PFE has a similar setup to 
MRNA here, both are attractive buys from a valuation and technical standpoint here and have been beaten down lately due to the situation with rates, banking woes and negative news about COVID vaccines, COVID lock downs, etc. (a general more negative perception of health measures taken by the US govt since 2020 likely part of the reason for the decline here)The companies still have valuable IP and profitable businesses that can rerate higher over time, specially now that the broad market appears to be trending up long term again.
Best of luck!
Cheers,
Ivan Labrie.
註釋
Target was hit but there is time left in the signal, a new trend signal can form if this holds up near the target.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。